Printer Friendly

ALS Therapy obtains United States patent.

ALS Therapy Development Foundation, Inc. (Cambridge, MA) has patented methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed. (US 7,211,602)
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Mar 1, 2007
Previous Article:Millenia Hope receives a grant from NIH to develop HIV therapeutics with Rutgers and the University of Pittsburgh.
Next Article:Universite Pierre et Marie Curie obtains United States patent.

Related Articles
Closing in on the Lou Gehrig's disease gene.
TKT updates status of erythropoietin litigation.
Good news.... and bad news. (Treatment News).
TKT announces issuance of two gene therapy patents.
Proteins mark ALS.
Power3 and The Methodist Hospital Research Institute form collaborative research agreement for neurodegenerative disease blood test serum proteins.
Avicena applies for patent covering composition for treating ALS.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters